[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-340308-105":59,"doc-detail-340308-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","radiopharmaceuticals-for-pancreatic-cancer-a-review-of-current-approaches-and-future-directions","Radiopharmaceuticals for Pancreatic Cancer: A Review of Current Approaches and Future Directions","","The poor prognosis of pancreatic cancer requires novel treatment options. This review examines the evolution of radiopharmaceuticals in the treatment of pancreatic cancer, highlighting established strategies such as peptide receptor radionuclide therapy (PRRT) for targeted and effective intervention versus conventional care. It notes the lack of approved radiopharmaceuticals for pancreatic cancer in Europe and reviews emerging agents including radiolabeled antibodies, peptides, and nanotechnological approaches.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/radiopharmaceuticals-for-pancreatic-cancer-a-review-of-current-approaches-and-future-directions/340308/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/radiopharmaceuticals-for-pancreatic-cancer-a-review-of-current-approaches-and-future-directions/340308.png","ImageObject",300,407,{"name":92,"@type":93},"Skyler","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-01","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why is a novel treatment approach needed for pancreatic cancer?","Question",{"text":112,"@type":113},"Pancreatic cancer has a poor prognosis and is difficult to treat, with high mortality driven by aggressive disease progression. The review emphasizes the need for new therapeutic options beyond conventional regimens.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What established radiopharmaceutical strategy is discussed?",{"text":117,"@type":113},"The review highlights peptide receptor radionuclide therapy (PRRT) as a targeted approach that can provide effective treatment compared with conventional options.",{"name":119,"@type":110,"acceptedAnswer":120},"Why does the review focus on new radiopharmaceuticals in Europe?",{"text":121,"@type":113},"It states that no radiopharmaceuticals are currently approved for pancreatic cancer treatment in Europe, motivating further research and development of new agents.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},340308,1790437075,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},2336464648746,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","pharmaceuticals  \nReview  \nRadiopharmaceuticals for Pancreatic Cancer: A Review of Current Approaches and Future Directions  \nSara Calistri 1,2, *, Giuseppe Ottaviano 2 and Alberto Ubaldini 2  \nCitation: Calistri, S.; Ottaviano, G.; Ubaldini, A. Radiopharmaceuticals for Pancreatic Cancer: A Review of Current Approaches and Future Directions. Pharmaceuticals 2024, 17, 1314. [https://doi.org/10.3390/](https://doi.org/10.3390/)[ ](https://doi.org/10.3390/)ph17101314  \nAcademic Editors: Ute Hennrich and Martina Benešová-Schäfer  \nReceived: 13 September 2024  \nRevised: 26 September 2024  \nAccepted: 27 September 2024  \nPublished: 1 October 2024  \nCopyright: © 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ([https://](https://)[ ](https://)[creativecommons.org/licenses/by/](creativecommons.org/licenses/by/)[ ](creativecommons.org/licenses/by/)[4.0/](4.0/)) .  \n1 Department of Pharmacy and Biotechnology, Alma Mater Studiorum, University of Bologna,  \n40126 Bologna, Italy  \n2 ENEA, Italian National Agency for New Technologies, Energy and Sustainable Economic Development, C.R. Bologna, Via Martiri di Monte Sole 4, 40129 Bologna, Italy; [giuseppe.ottaviano@enea.it](giuseppe.ottaviano@enea.it) (G.O.); [alberto.ubaldini@enea.it](alberto.ubaldini@enea.it) (A.U.)  \n* Correspondence: [sara.calistri2@unibo.it](sara.calistri2@unibo.it)  \nAbstract: The poor prognosis of pancreatic cancer requires novel treatment options. This review examines the evolution of radiopharmaceuticals in the treatment of pancreatic cancer. Established strategies such as peptide receptor radionuclide therapy (PRRT) offer targeted and effective treatment, compared to conventional treatments. However, there are currently no radiopharmaceuticals approved for the treatment of pancreatic cancer in Europe, which requires further research and novel approaches. New radiopharmaceuticals including radiolabeled antibodies, peptides, and nanotechnological approaches are promising in addressing the challenges of pancreatic cancer therapy. These new agents may offer more specific targeting and potentially improve efficacy compared to traditional therapies. Further research is needed to optimize efficacy, address limitations, and explore the overall potential of these new strategies in the treatment of this aggressive and harmful pathology.  \nKeywords: radiopharmaceuticals; pancreatic cancer; radionuclides; PRRT; NETs  \n1. Introduction  \nPancreatic cancer is a highly malignant tumor of the digestive tract, which is difficult to treat and seriously endangers human life and health [1] . It accounts for almost as many deaths (466,000) as cases (496,000) because of its poor prognosis, and is the seventh leading cause of cancer death in both sexes [2] . According to Ferlay et al. in 2016, pancreatic cancer is projected to become the third leading cause of cancer death in the EU by 2025, surpassing colorectal cancer and accounting for 25% of all cancer deaths [3] . The World Health Organization (WHO) in 2020 revealed that among people of all ages and considering both sexes, pancreatic cancer has been identified as the third leading cancer-related cause of death in different countries including Italy, Germany, Austria, Czechia, Hungary, Malta, Spain, Switzerland and USA [4] . For some other countries, in particular, Finland, Qatar, Benin and Guadeloupe, pancreatic cancer was revealed to be the second leading cause of death among all the different types of cancer in 2020 (among females aged ≥ 70 years [4] .  \nTumors of pancreas are divided into two groups: (1) Non-endocrine pancreas tumors (2) Endocrine pancreas tumors [5,6] . Non-endocrine pancreas tumors are categorized as benign and malignant [5,6] . Benign non-endocrine tumors of the pancreas: adenoma, cystadenoma, lipoma, fibroma, hemangioma, lymphangioma and neuroma [5,6] . Malignant tumors of t","cbCaifhgLK9InVKZ","https://ap.wps.com/l/cbCaifhgLK9InVKZ","pdf",861096,21,"English","# Introduction\n## Radiopharmaceutical strategies for pancreatic cancer\n## Emerging agents and future directions","[{\"question\":\"Why is a novel treatment approach needed for pancreatic cancer?\",\"answer\":\"Pancreatic cancer has a poor prognosis and is difficult to treat, with high mortality driven by aggressive disease progression. The review emphasizes the need for new therapeutic options beyond conventional regimens.\"},{\"question\":\"What established radiopharmaceutical strategy is discussed?\",\"answer\":\"The review highlights peptide receptor radionuclide therapy (PRRT) as a targeted approach that can provide effective treatment compared with conventional options.\"},{\"question\":\"Why does the review focus on new radiopharmaceuticals in Europe?\",\"answer\":\"It states that no radiopharmaceuticals are currently approved for pancreatic cancer treatment in Europe, motivating further research and development of new agents.\"}]","Radiopharmaceuticals for Pancreatic Cancer: A Review of Current Approaches and Future Directions | PDF",1790035685,53,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/595f5ed8545e20a3ad90abcbfeb6c4fc.webp",983,1390,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/84a550eebe430927c2105896cf3f5c54.webp",982,1388,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/26396e7b249c27ce3f2106e0708dc917.webp",981,1387,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6e324408b7596cd3db72f8fba8d19e80.webp",980,1385]